The discovery of RNAi dates back to the 1990s when researchers observed unexpected gene silencing in plants and fungi. In 1998, Andrew Fire and Craig Mello published a groundbreaking study ...

This article explores how challenges such as sequence optimization, immune activation and off-target effects are being addressed to enhance the safety, durability and efficacy of RNA therapeutics.

Researchers have discovered RNA mechanisms that may lead to more effective, durable and targeted treatments for conditions like high cholesterol, liver diseases and cancers. RNA interference (RNAi) ...

Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

RNA interference (RNAi) therapeutics have garnered significant attention in clinical research due to their potential for treating various diseases, including genetic disorders, viral infections and ...

With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...

A new possibility for managing cardiovascular disease through RNA interference (RNAi) gene therapies. As cardiovascular diseases continue to be the leading cause of death globally, this technology ...

Nearly 1.3 billion adults around the world have clinically high blood pressure, many of whom may be unaware that they are living with this condition. Nearly 1.3 billion adults around the world have ...

Ask a friend what DNA is and, chances are, they have a general idea. Seventy years after scientists discovered the two-stranded helix, DNA (deoxyribonucleic acid) is widely understood as the keeper of ...